01:30 AM EST, 11/04/2026 (MT Newswires) -- Fresenius (FRE.F) improved its core EPS growth guidance for full-year 2026, according to a Wednesday filing. The therapy-focused healthcare company now expects core EPS growth in the upper half of the 10% to 15% range in constant currency, compared with earlier forecasts within the 10% to 15% range. Meanwhile, the company reiterated its organic revenue growth guidance of between 4% and 7%.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.